Replies to post #287183 on NorthWest Biotherapeutics Inc (NWBO)

[marzan]

longfellow/meirluc/alphapuppy/Ex et al., how does that PFS (they are all like Brad) statement that LL uttered figure into this P value or PFS k-m curve that alphapuppy gave us. I think it was like 50 progression free patients she was talking about. This 50 number is like Adjudicated data while the trial is still blinded. I bet if someone like alphapuppy account for this 50 PFS free number into his k-m chart, I bet we can declare PFS efficacy already. Hope my question is clear to you geniuses.

[meirluc]

Hi Longfellow,

Many thanks for your input. I think you are right in believing that with alphapuppy's model = reality, we would have had way back then an AA in hand.

I am now looking at this in a very simplistic way.

There are plenty of records indicating that many patients who received DCVax-L and became post 5 year survivors, unfortunately suffered the final event within the following years.

Obviously, while the rate of progression diminishes with time, it is unfortunately still alive and well for many years.

I nevertheless suspect that in comparison to SOC and other treatments, DCVax-L at every timeline effects a greater decrease in the rate of progression.

I hope that the published results of this trial will give us a better understanding of the effect DCVax-L has on the rates of progression during different timelines of the GBM illness.